UCB SA develops products for neurology and immunology diseases globally. Primary products include Cimzia, Vimpat, Keppra, Briviact, Neupro, Nayzilam, Zyrtec, and Xyzal. Additionally, it offers Evenity, Bimzelx, and Fintepla for various conditions. The company is also developing several treatments, including rozanolixizumab, Zilbrisq, dapirolizumab pegol, fenfluramine, doxecitine, STACCATO alprazolam, bepranemab, minzasolmin, UCB0222, UCB1381, and UCB9741. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
| Indicator | Value |
|---|---|
| PER | 30.5 |
| EV/EBITDA | 22.1 |
| Price/Free Cash Flow' | 35.3 |
| ROIC | 9.7% |
| Net Debt/EBITDA | 0.8 |